{"id":"NCT05281523","sponsor":"GlaxoSmithKline","briefTitle":"Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)","officialTitle":"A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-04-18","primaryCompletion":"2024-07-12","completion":"2024-08-06","firstPosted":"2022-03-16","resultsPosted":"2025-09-09","lastUpdate":"2025-09-09"},"enrollment":264,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Nasal Polyps"],"interventions":[{"type":"BIOLOGICAL","name":"Depemokimab (GSK3511294)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Depemokimab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).","primaryOutcome":{"measure":"Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read)","timeFrame":"Baseline (Day 1) and at Week 52","effectByArm":[{"arm":"Depemokimab","deltaMin":-0.5,"sd":0.14},{"arm":"Placebo","deltaMin":0.1,"sd":0.15}],"pValues":[{"comp":"OG000 vs OG001","p":"0.004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":84,"countries":["United States","China","Italy","Japan","Poland","Romania","Spain","Sweden","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["40037388"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":129},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","COVID-19","Nasal congestion"]}}